Retatrutide is not an approved drug, and there is no lawful way to compound it. Not through a 503A pharmacy, not through a 503B outsourcing facility, not with a prescription, and not with a consent form.
It is nonetheless being sold and administered at scale. If someone has offered to supply it to your practice, this is what you are being offered.
What retatrutide is
Retatrutide is an investigational molecule developed by Eli Lilly, a triple agonist being studied for obesity and related conditions. Trial results have generated significant attention, which is precisely why a gray market formed around it before the science finished.
As of September 2026 it is not FDA approved for any indication. Eli Lilly’s August 5, 2026 SEC filing says it plans to submit a Biologics License Application in the first quarter of 2027. FDA review follows a filing, so approval would come later still.
Why it cannot be compounded
Compounding is not a general permission. It runs through specific statutory pathways, and retatrutide does not qualify for any of them:
- It is not a component of an FDA-approved drug. Compounding generally works from approved drug components; retatrutide is not one.
- There is no USP monograph establishing standards for it.
- It does not appear on FDA’s bulk drug substance lists for either 503A or 503B compounding.
Those three facts close every door. There is no legal pathway to compound retatrutide under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. A pharmacy offering it is not operating in a gray area. It is outside the framework.
What is actually in the vials
The retatrutide products circulating appear to be made with research-grade active ingredient, which is itself not permitted for use in human drugs.
Research-grade material is manufactured to a different standard than pharmaceutical-grade. It is not made for administration to people, and it is not subject to the controls that pharmaceutical manufacturing requires. Purity, sterility, endotoxin content, and actual concentration are not assured in any way you can rely on.
When a vial arrives labeled “for research use only,” that label is not a formality. It is the manufacturer stating that the contents are not intended to go into a human being.
The FDA has been explicit
FDA states that retatrutide cannot be used in compounding under federal law. It has sent warning letters to sellers including GLP-1 Solution (September 2025), Gram Peptides (March 2026) and Peptide Partners (August 2026), and in the last two it disregarded the research-use-only label.
This is not an area where enforcement posture is ambiguous or where the agency has stayed quiet.
Adverse events are how this surfaces
This matters for a practice owner for a simple reason: adverse outcomes are how these products come to light. The product does not need to be discovered on a shelf. It gets discovered because a patient had a problem.
What exposure looks like for the practice
- Administering an unapproved drug made with material not permitted in human medicines.
- Professional discipline for the prescribing or supervising clinician. This attaches to a license, personally.
- Malpractice coverage questions. Carriers are not obliged to defend the administration of an unapproved substance; read your policy before assuming.
- Advertising exposure if the practice promoted it.
- Certification risk. If you hold LegitScript or a comparable certification, this is squarely the kind of thing that ends it.
- No informed consent that cures it. A patient cannot consent their way into a lawful administration of an unlawful product.
What to say to the vendor
If a supplier is offering retatrutide, ask three questions:
- Under which statutory pathway is this being compounded, 503A or 503B?
- Where does the active ingredient appear on FDA’s bulk substances list?
- Is the API pharmaceutical grade, and can you produce documentation?
There are no satisfactory answers. The value of asking is that the response tells you what kind of counterparty you are dealing with, and it creates a record that you asked.
What to offer patients instead
Patients asking for retatrutide are usually asking for a better outcome than they are getting, not for that specific molecule. There are approved medications for chronic weight management, and there is a real clinical conversation to have about candidacy, dosing, adherence, and expectations.
“We do not offer that, and here is why” is a defensible position that also builds trust. Practices that hold that line tend to be the ones still operating when enforcement catches up with the ones that did not.
Where MDside stands
Our providers do not prescribe retatrutide, and our protocols do not permit it. That is not caution for its own sake. There is no version of this that is lawful today, and a practice that offers it is one adverse event away from a very bad month.
See what is included, or read what “FDA approved” actually means.
The disclaimer these products ship behind is worth understanding on its own terms: why “research use only” is not a legal shield.
Related reading
Frequently asked questions
Is retatrutide FDA approved?
No. It is investigational and not approved for any indication. Lilly plans to submit a Biologics License Application in the first quarter of 2027, per its August 2026 SEC filing, and approval would follow FDA review.
Can a compounding pharmacy legally make retatrutide?
No. It is not a component of an approved drug, has no USP monograph, and is not on FDA’s bulk substance lists, so no 503A or 503B pathway applies.
What if the patient signs a waiver?
A waiver does not make administration lawful and does not transfer regulatory responsibility away from the prescriber or the practice.
What about “research use only” retatrutide?
That labeling indicates the material is not intended for human administration. Research-grade ingredients are not permitted in human drugs.
When could this change?
If and when FDA approves it, following a completed application and review. Until then, the analysis above does not change.
General information about regulatory status, not legal or clinical advice, and not a treatment recommendation. Regulatory status can change. Verify current FDA status before making any decision, and consult healthcare counsel.